Expert insight 6 Jun 2017

Behind the Numbers: Pharma and Global Health

The most indisputable of all facts on global health is that we’re living longer and healthier lives than ever, and in an era of continuous health improvement. What were once considered life-threatening diseases are now manageable conditions, and not just for patients, but for our health systems also. Where Hepatitis C, for example, would have...

Read more
Infographic 2 Jun 2017

Fight the Fakes Infographic – Same Packaging, Same Shape and Same Color… But Fakes! (Spanish Version)

Read more
Expert insight 2 Jun 2017

Unlikely bedfellows join to fight superbugs

In January 2016, more than 100 companies and industry associations had signed a Declaration on Combatting Antimicrobial Resistance at the World Economic Forum in Davos, followed by a Roadmap of several big pharma at the UN High-Level Meeting in September 2016 – a common framework of principles for global measures to curb the development of antibiotic resistance. The “AMR Industry Alliance” now...

Read more
Press release 31 May 2017

IFPMA contribution to key global health discussions @WHA70 (22-31 May 2017)

Geneva, 31 May 2017 – Starting with the election of Dr Tedros Adhanom Ghebreyesus as Director-General of the World Health Organization (WHO), deliberations during the 70th World Health Assembly (WHA70) in Geneva this week touched upon key public health and global security issues such as cancer prevention and control, antimicrobial resistance, pandemic influenza preparedness, falsified...

Read more
Statement 30 May 2017

WHO WHA 70 agenda item 15.6 Cancer prevention and control in the context of an integrated approach

Delivered by Fumie Griego, Assistant Director General The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) welcomes the resolution and its integrated approach to cancer prevention and control. The economic impact of cancer continues to rise, while the funding to support these efforts have not kept pace. All sectors must come together to ensure that high quality...

Read more
Statement 29 May 2017

WHO WHA 70 agenda item 15.2 Draft global action plan on the public health response to dementia

Delivered by Vanessa Peberdy, Manager, Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our perspective on dementia. IFPMA represents leading research-based pharmaceutical companies, as well as national and regional industry associations worldwide. IFPMA commends the WHO Secretariat for its vision and...

Read more
Statement 29 May 2017

WHO WHA 70 item 13.6 Member State mechanism on SSFFC

WHA70 agenda item 13.6  Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products Delivered by Cyntia Genolet, Manager, Regulatory and Health Policy Progress toward health improvement will not be achievable without a consistent and constant fight against falsified medicines. Falsified medicines deliberately and deceitfully attempt to pass themselves off as genuine approved medicines. They represent a serious...

Read more
Expert insight 29 May 2017

Life-course vaccination: for today, not tomorrow

Thinking about how to be a healthy older person is like thinking about glaciers crashing into Arctic seas as a result of climate change. Too far away to imagine, and we’ll worry when the effects reach our doorsteps. In reality, the challenge is here today asking all of us, at any age, to look ahead...

Read more
Statement 27 May 2017

WHO WHA 70 agenda item 13.3 Addressing the global shortage of, and access to, medicines and vaccines

Delivered by Laetitia Bigger, Director, Vaccines Policy IFPMA welcomes WHO’s efforts in developing a framework to avert shortages. While supply is one factor, shortages are influenced by a range of issues, such as unpredictable country demand, complex regulatory requirements, and lack of timely communication as referenced in paper A70/20. We call for the timely dialogue...

Read more
Statement 25 May 2017

WHO WHA 70 item 12.5 Review of the Pandemic Influenza Preparedness Framework

Delivered by Paula Barbosa, Manager, Vaccines Policy IFPMA reiterate our support for the aim of the WHO PIP Framework to improve pandemic influenza preparedness and response. We welcome the progress made since the establishment of this Framework and remain committed partners in this initiative. While we continue to support the PIP Framework, we believe there...

Read more
Statement 24 May 2017

WHO WHA 70 Item A70/12 Antimicrobial resistance

Delivered by Nina Grundmann, Manager, Global Health Policy, IFPMA IFPMA commends the World Health Organization on the implementation of its AMR GAP and the 67 Member States which have now completed their national action plans. Our industry is at the forefront of leading action to address AMR and is committed to continuing to engage with...

Read more
Expert insight 24 May 2017

Supply & demand: fighting falsified medicines on two fronts

As falsified medicines are debated this week at the World Health Assembly, IFPMA shares what the biopharmaceutical is doing to combat this risk to individual and public health.    If there’s one place not to take a gamble, it’s on whether or not a medicine is real or falsified. Yet in the last weeks alone...

Read more